Evidence map›Paper›PMID 33619413›Full record

ArticleNeuroscience and behavioral physiology2021

The Novel Coronavirus Infection (COVID-19) and Nervous System Involvement: Mechanisms of Neurological Disorders, Clinical Manifestations, and the Organization of Neurological Care.

E I Gusev, M Yu Martynov, A N Boyko, I A Voznyuk, N Yu Latsh, S A Sivertseva, N N Spirin, N A Shamalov

Open access · bronzeAbstract read
In one paragraph

Article in Neuroscience and behavioral physiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

E I GusevPirogov Russian National Research Medical University, Russian Ministry of Health, Moscow, Russia.
M Yu MartynovPirogov Russian National Research Medical University, Russian Ministry of Health, Moscow, Russia.
A N BoykoPirogov Russian National Research Medical University, Russian Ministry of Health, Moscow, Russia.
I A VoznyukDzhanelize Research Institute of Emergency Medicine, St. Petersburg, Russia.
N Yu LatshPirogov Russian National Research Medical University, Russian Ministry of Health, Moscow, Russia.
S A SivertsevaTyumen Regional Multiple Sclerosis Center, Tyumen, Russia.
N N SpirinYaroslavl State Medical University, Yaroslavl, Russia.
N A ShamalovPirogov Russian National Research Medical University, Russian Ministry of Health, Moscow, Russia.
Pirogov Russian National Research Medical University · RUSaint-Petersburg I. I. Dzhanelidze Research Institute of Emergency Medicine · RUTyumen Regional Oncological Dispensary · RUYaroslavl State Medical Academy · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The new coronavirus SARS-CoV-2 and the disease it causes COVID-19 involves not only respiratory system damage, but can also lead to disorders of the central and peripheral nervous system, as well as the muscular system. This article presents published data and our own observations on the course of neurological disorders in COVID-19 patients. There is a relationship between the severity of COVID-19 and the severity and frequency of neurological manifestations. Severe neurological disorders are mostly seen in severe cases of COVID-19 and include acute cerebrovascular accidents (aCVA), acute necrotizing encephalopathy, and Guillain-Barré syndrome. Factors potentially complicating the course of COVID-19 and increasing the development of neurological complications include arterial hypertension, diabetes mellitus, and chronic cardiac and respiratory system diseases. Questions of the possible effects of human coronaviruses on the course of chronic progressive neurological diseases are addressed using multiple sclerosis (MS) as an example. We discuss the management of patients with aCVA and MS depending on the risk of developing coronavirus infection.

Indexed as

acute necrotizing encephalopathycoronavirusesCOVID-19 SARS-CoV-2Guillain–Barré syndromemultiple sclerosismuscular systemnervous systemstroke

Identifiers

PMID33619413
PMCPMC7889305
OpenAlexW3130626259

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.